Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trialAleix Prat, Joaquín Gavilá, Montserrat Muñoz-Mateu et al.|The Lancet Oncology|2019Cited by 199
A core outcome set for maternal and neonatal health research and surveillance of emerging and ongoing epidemic threats (MNH-EPI-COS): a modified Delphi-based international consensusVerónica Pingray, Mercedes Bonet, Karen Klein et al.|EClinicalMedicine|2025Cited by 8